Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.

Arthritis Research & Therapy
Kosuke EbinaMakoto Hirao

Abstract

This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of 7 biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF), one of the janus kinase inhibitors, in bDMARDs-naïve and bDMARDs-switched patients with rheumatoid arthritis (RA). This study assessed 3897 patients and 4415 treatment courses with bDMARDs and TOF from 2001 to 2019 (2737 bDMARDs-naïve courses and 1678 bDMARDs-switched courses [59.5% of switched courses were their second agent], female 82.3%, baseline age 57.4 years, disease duration 8.5 years; rheumatoid factor positivity 78.4%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate 4.3; concomitant prednisolone [PSL] dose 6.1 mg/day [usage 42.4%], and methotrexate [MTX] dose 8.5 mg/week [usage 60.9%]). Treatment courses included abatacept (ABT; n = 663), adalimumab (ADA; n = 536), certolizumab pegol (CZP; n = 226), etanercept (ETN; n = 856), golimumab (GLM; n = 458), infliximab (IFX; n = 724), tocilizumab (TCZ; n = 851), and TOF (n = 101/only bDMARDs-switched cases). Drug discontinuation reasons (categorized into lack of effectiveness, toxic adverse events, non-toxic reasons, or remission) and rates were estimated at 36 m...Continue Reading

References

Jan 11, 2005·Annals of the Rheumatic Diseases·E HjardemUNKNOWN Danish Database for Biological Therapies in Rheumatology Study Group
Jun 15, 2007·Bone Marrow Transplantation·L ScruccaF Aversa
May 1, 2009·Arthritis and Rheumatism·Sophie Martin Du PanUNKNOWN Swiss Clinical Quality Management Physicians
Nov 19, 2010·Rheumatology·Julia F SimardJohan Askling
May 10, 2011·Annals of the Rheumatic Diseases·Henrik Christian LeffersUNKNOWN all departments of rheumatology in Denmark
Mar 9, 2013·Scandinavian Journal of Rheumatology·Y HishitaniA Kumanogoh
Nov 29, 2013·Annals of the Rheumatic Diseases·M NeoviusUNKNOWN ARTIS Study Group
Feb 18, 2015·Nature Reviews. Rheumatology·Josef S Smolen, Daniel Aletaha
Feb 10, 2018·Seminars in Arthritis and Rheumatism·Carlos Fernández-DíazRicardo Blanco
Oct 14, 2018·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Almut Dutz, Steffen Löck

❮ Previous
Next ❯

Citations

Jul 6, 2021·Therapeutic Advances in Musculoskeletal Disease·Jean-Guillaume LetarouillyJulien Paccou
Aug 6, 2021·Open Access Rheumatology : Research and Reviews·Ilaria Bertoldi, Roberto Caporali
Aug 21, 2021·Biologics : Targets & Therapy·Kate E FindeisenAndrew J K Ostor

❮ Previous
Next ❯

Software Mentioned

R
EZR

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.